Navigation Links
Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data At The IDF's 20th World Diabetes Congress
Date:10/21/2009

MONTREAL, Oct. 21 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity, today presented dose optimization data from its Phase 2 clinical study of otelixizumab in subjects with type 1 diabetes. Otelixizumab is a targeted T-cell immunomodulator currently being evaluated in DEFEND, a Phase 3 clinical study in subjects with new-onset autoimmune type 1 diabetes. Data from the Phase 2 dose optimization study, which were used to determine the dose in the DEFEND trial, were presented at the International Diabetes Federation's 20th World Diabetes Congress currently taking place in Montreal, Canada.

In an oral presentation entitled "Otelixizumab - Dose regimen optimization of a humanized aglycosylated anti-CD3 monoclonal antibody in adult subjects with type 1 diabetes mellitus," Dr. Louis Vaickus, Chief Medical Officer at Tolerx, presented preliminary data from the Phase 2 otelixizumab dose optimization clinical study, referred to as TTEDD.

In a previous investigator-sponsored Phase 2 study, a high dose (48-64 mg) of otelixizumab was shown to preserve natural insulin production for up to 48 months after a single course of treatment. Subsequently, Tolerx initiated TTEDD to investigate alternative dosing regimens that would minimize adverse events, while maintaining durable clinical activity. A cumulative dose of 3.1 mg of otelixizumab administered over 8 days was identified as the optimized dose suitable for further evaluation. In TTEDD, this dosing regimen resulted in preservation of beta cell function (as measured by C-peptide, a common marker for endogenous insulin production) for up to 12 months in patients with autoimmune new-onset type 1 diabetes with no observation of significant safety issues.

About the DEFEND Study

DEFEND (Durable Response Therapy Evaluation
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Tolerx Announces Amendment to Phase 3 DEFEND Protocol
2. Tolerx Expands Phase 3 DEFEND Trial of Otelixizumab in Europe
3. Laureate Announces Manufacturing Agreement with Tolerx
4. Tolerx Named as One of the Fierce 15 Biotech Companies of 2008
5. Sinobiopharma Presents Highlights from Unaudited First Quarter Financial Results for the 3 Month Period Ended August 31, 2009
6. AlphaHelix Presents AmpXpress(TM) at the BIOTECHNICA Show
7. Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
8. InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting
9. NovaBay(R) Presents Data Confirming Its Aganocide(R) Compounds Are Effective In Killing Bacteria That Have Developed Multidrug-Resistance
10. Novexel Presents 16 Posters and one Slide Presentation at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Meeting in San Francisco
11. Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... OAK RIDGE, Tenn., July 24, 2014 -- A novel ... at the Department of Energy,s Oak Ridge National Laboratory ... known for its unusual physical and electrochemical properties. ... examined how oxygen affects the surface of a perovskite ... electronic behavior. The new avenue to understand surface behavior ...
(Date:7/24/2014)... Security forces worldwide rely on sophisticated equipment, trained ... other public areas against terrorist attacks. A revolutionary ... about to make their job much easier. , ... Patolsky of Tel Aviv University ,s School of ... developed by the Herzliya company Tracense, picks up ...
(Date:7/24/2014)... DUBLIN , July 24, 2014 ... the "Global Cell Culture Market 2014-2018" report ... Cell culture is the in vitro ... such as research, cell studies, and biopharmaceutical production. Cell ... vaccine production. Cell culture instruments and cell culture consumables ...
(Date:7/24/2014)... Three companies from the angelMD network ... C Competition. Out of 700 competition entrants, Chiron Health, ... semi-final round. In this round twenty teams are invited ... with mentoring from thought-leaders and medical entrepreneurs from all ... angelMD commitment to the Livestrong vision around the Big ...
Breaking Biology Technology:ORNL study reveals new characteristics of complex oxide surfaces 2Nano-sized chip 'sniffs out' explosives far better than trained dogs 2Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 23 angelMD Startups Make Livestrong Big C Semi-finals 2
... nothing in record numbers. , ,In 2003, an estimated 5 ... as LiveJournal , Movable Type , and Weblogger ... a New Year's resolution. , ,A November study of eight ... 20 percent of all blogs (short for "Web logs") are abandoned ...
... cursed) Sarbanes-Oxley Act of 2002 (Sarbox), many publicly ... financial recording and accounting practices and updated their ... whether privately held companies and non-profits should be ... public companies. Are taking these kinds of measures ...
... , a provider of business solutions that connect ... announced today that Hance Company of Plymouth, Minn., ... solution for integration directly with Hance's Ezone parts ... , ,Under the agreement, ARI will host ...
Cached Biology Technology:Who Gives a Blog? 2Sarbanes-Oxley for the Rest of Us 2Sarbanes-Oxley for the Rest of Us 3Sarbanes-Oxley for the Rest of Us 4
(Date:7/24/2014)... Environmental cleanup experts gathered at NJIT this week for ... by the U.S. Environmental Protection Agency (EPA) to dredge ... Passaic River. , The EPA has called the plan, ... sediments and capping sections of the riverbed, one of ... material would be dredged and disposed off-site. , "We ...
(Date:7/24/2014)... For years, researchers and patients have hoped that embryonic ... in the bodycould provide insight into numerous diseases perhaps ... been hampered by the inability to transfer research and ... in part because human ESCs are "primed" and slightly ... Theunissen, Benjamin Powell, and Haoyi Wang, who are scientists ...
(Date:7/24/2014)... the primordial soup in which life arose have been maintained ... of East Anglia. , Research published today in the ... yeast and very likely also in animals still perform ancient ... life some four billion years ago. , The primordial ... ocean as a result of the combination of metals, gases ...
Breaking Biology News(10 mins):Experts Weigh the Pros and Cons of a $1.7 Billion EPA Cleanup Plan for the Passaic River at an NJIT 2Whitehead Institute researchers create 'naïve' pluripotent human embryonic stem cells 2
... research in France on patients diagnosed with cryptococcosis ... patients infected by HIV and who are profoundly ... 5 2007 in PLoS Medicine, uncovers parameters associated ... sex and the infecting serotype. In light of ...
... In a venture once thought to lie outside the ... Beth Israel Deaconess Medical Center have captured and sequenced ... Tyrannosaurus rex. The protein fragments—seven in all—appear to most ... present day chickens, lending support to a recent and ...
... international consortium of researchers has published the genome sequence ... the chimpanzee and human genomes. Published April 13 in ... reveals that the three primate species share about 93 ... among their genes. , In its paper, the Rhesus ...
Cached Biology News:New recommendations against a major opportunistic infection -- cryptococcosis 2New recommendations against a major opportunistic infection -- cryptococcosis 3Protein fragments sequenced in 68 million-year-old Tyrannosaurus rex 2Protein fragments sequenced in 68 million-year-old Tyrannosaurus rex 3Protein fragments sequenced in 68 million-year-old Tyrannosaurus rex 4Analysis of rhesus monkey genome uncovers genetic differences with humans, chimps 2Analysis of rhesus monkey genome uncovers genetic differences with humans, chimps 3
... Useful as a positive control for ... to chromatin in vivo is a crucial ... extent of crosslinking is probably the most ... subsequent immunoprecipitation step should be taken into ...
Mouse monoclonal [M2II-12] to MRP2 ( Abpromise for all tested applications). entrezGeneID: 1244 SwissProtID: Q92887...
The Programmable MP-5000P-F Power Supply can be applied for any Microfluidic application....
Rab GDP dissociation inhibitor beta...
Biology Products: